Use of combined FDG-PET/CT in diagnosing infectious complications in patients treated with intensive chemotherapy and stem cell transplant recipients for haematological malignancy.

Use of combined FDG-PET/CT in diagnosing infectious complications in patients treated with intensive chemotherapy and stem cell transplant recipients for haematological malignancy. - Diagnostic value of FDG-PET/CT in febrile neutropenia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30325

Enrollment

Registered

2006-09-15

Start date

2006-07-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febriele neutropenie febrile neutropenia fever after chemotherapy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - admission and treatment at the department of hematology because of a hematological malignancy - expected duration of neutropenia >7 days;and any of the following: * C-reactive proteïn > 50 mg/l * febrile neutropenia > 3-4 days despite aimed empirical or aimed antibiotic therapy * persistant bacteraemia with coagulase negative Staphylococci * pulmonary HRCT inidicated because of suspected pulmonary Aspergillosis

Exclusion criteria

Exclusion criteria: - hemodynamic instablility - diabetus millitus in which insulin has to be administered within 4 hours of the PET-scan either bloodglucose levels exceed 15 mmol.l - pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
In the analysis the correlation between clinical defined infection (CDI) or microbiologically defined infection (MDI) and abnormalities on FDG-PET will be studied.	—

Countries

Netherlands

Outcome results